Weightlifter receives sanction

  • Doping Violation Update

The Australian Sports Anti-Doping Authority (ASADA) today acknowledged the decision of the Australian Weightlifting Federation Ltd (AWF) to sanction athlete Simon McCoy for the presence of the metabolite of a prohibited substance and use of a prohibited substance.

Mr McCoy returned an Adverse Analytical Finding (AAF) from an in-competition doping control test at the Victorian Weightlifting Senior and Junior Championships on 14 July 2018.

His sample was analysed at the Australian Sports Drug Testing Laboratory, part of the National Measurement Institute, which detected the presence of Di-Hydroxy LGD-4033 (metabolite of LGD-4033).

LGD-4033 is prohibited in and out-of-competition under the S1 classification of Anabolic Agents.

The AWF imposed a four-year ban on Mr McCoy commencing on 7 September 2018.

Mr McCoy will be eligible to return to competition on 7 September 2022.

Additional information on the prohibited substance

LGD-4033, originally developed for the treatment of muscle wasting conditions such as aging, osteoporosis, muscular dystrophy and cancer, is promoted as a selective non-steroidal anabolic agent.

It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use. However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown.

It should be noted that a number of SARMs have associated health-risks, particularly for the heart and liver.